Next Article in Journal
Genipin Derivatives Protect RGC-5 from Sodium Nitroprusside-Induced Nitrosative Stress
Next Article in Special Issue
Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders
Previous Article in Journal
Influence of Bxpel1 Gene Silencing by dsRNA Interference on the Development and Pathogenicity of the Pine Wood Nematode, Bursaphelenchus xylophilus
Previous Article in Special Issue
New Insights to Clathrin and Adaptor Protein 2 for the Design and Development of Therapeutic Strategies
Open AccessArticle

Statin Therapy and the Development of Cerebral Amyloid Angiopathy—A Rodent in Vivo Approach

Department of Neurology and Neurophysiology, University Freiburg, 79106 Freiburg, Germany
Department of Neurology, Universitätsmedizin Mannheim, Heidelberg University, 68167 Mannheim, Germany
Computer Assisted Clinical Medicine, Heidelberg University, 68167 Mannheim, Germany
Nervous System Department, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Amal Kaddoumi
Int. J. Mol. Sci. 2016, 17(1), 126;
Received: 16 December 2015 / Revised: 4 January 2016 / Accepted: 12 January 2016 / Published: 19 January 2016
(This article belongs to the Special Issue Amyloid-beta and Neurological Diseases)
Background: Cerebral amyloid angiopathy (CAA) is characterized by vascular deposition of amyloid β (Aβ) with a higher incidence of cerebral microbleeds (cMBs) and spontaneous hemorrhage. Since statins are known for their benefit in vascular disease we tested for the effect on CAA. Methods: APP23-transgenic mice received atorvastatin-supplemented food starting at the age of eight months (n = 13), 12 months (n = 7), and 16 months (n = 6), respectively. Controls (n = 16) received standard food only. At 24 months of age cMBs were determined with T2*-weighted 9.4T magnetic resonance imaging and graded by size. Results: Control mice displayed an average of 35 ± 18.5 cMBs (mean ± standard deviation), compared to 29.3 ± 9.8 in mice with eight months (p = 0.49), 24.9 ± 21.3 with 12 months (p = 0.26), and 27.8 ± 15.4 with 16 months of atorvastatin treatment (p = 0.27). In combined analysis treated mice showed lower absolute numbers (27.4 ± 15.6, p = 0.16) compared to controls and also after adjustment for cMB size (p = 0.13). Conclusion: Despite to a non-significant trend towards fewer cMBs our results failed to provide evidence for beneficial effects of long-term atorvastatin treatment in the APP23-transgenic mouse model of CAA. A higher risk for bleeding complications was not observed. View Full-Text
Keywords: CAA; transgenic mice; APP23; statins; cerebral microbleeds; amyloid CAA; transgenic mice; APP23; statins; cerebral microbleeds; amyloid
Show Figures

Figure 1

MDPI and ACS Style

Reuter, B.; Venus, A.; Grudzenski, S.; Heiler, P.; Schad, L.; Staufenbiel, M.; Hennerici, M.G.; Fatar, M. Statin Therapy and the Development of Cerebral Amyloid Angiopathy—A Rodent in Vivo Approach. Int. J. Mol. Sci. 2016, 17, 126.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

Back to TopTop